港股异动 | 复锐医疗科技(01696)涨超10% 公司称达希斐在华商业化工作正稳步推进

智通财经2025-07-29

智通财经APP获悉，复锐医疗科技(01696)涨超10%，本月股价已累涨超四成。截至发稿，涨10.45%，报6.45港元，成交额1111.17万港元。消息面上，7月28日晚，复锐医疗科技公布，公司知悉市场对其再授权产品RT002(中国境内商标达希斐®，英文商标 DAXXIFY®，通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。公司仅此说明，于该公告日期，该...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555086457?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-29 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555086457","market":"sh","top_or_hot":-1,"title":"港股异动 | 复锐医疗科技(01696)涨超10% 公司称达希斐在华商业化工作正稳步推进","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，复锐医疗科技(01696)涨超10%，本月股价已累涨超四成。截至发稿，涨10.45%，报6.45港元，成交额1111.17万港元。消息面上，7月28日晚，复锐医疗科技公布，公司知悉市场对其再授权产品RT002(中国境内商标达希斐®，英文商标 DAXXIFY®，通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。公司仅此说明，于该公告日期，该...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322976.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 复锐医疗科技(01696)涨超10% 公司称达希斐在华商业化工作正稳步推进</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 复锐医疗科技(01696)涨超10% 公司称达希斐在华商业化工作正稳步推进\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 10:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1322976.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，复锐医疗科技(01696)涨超10%，本月股价已累涨超四成。截至发稿，涨10.45%，报6.45港元，成交额1111.17万港元。消息面上，7月28日晚，复锐医疗科技公布，公司知悉市场对其再授权产品RT002(中国境内商标达希斐®，英文商标 DAXXIFY®，通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。公司仅此说明，于该公告日期，该...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1322976.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1322976.html","article_id":"2555086457","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555086457","pubTimestamp":1753757851,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，复锐医疗科技涨超10%，本月股价已累涨超四成。截至发稿，涨10.45%，报6.45港元，成交额1111.17万港元。消息面上，7月28日晚，复锐医疗科技公布，公司知悉市场对其再授权产品RT002于中国内地的商业化进展持续关注。公司仅此说明，于该公告日期，该产品在中国内地的商业化工作正稳步推进。公司对该产品在中国市场的应用前景充满信心，并将根据实际进展适时披露进一步信息。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1585":"昨日强势股","BK1593":"医美概念股","01696":"复锐医疗科技","BK1100":"医疗保健设备"},"translate_title":"Changes in Hong Kong stocks | Furui Medical Technology (01696) rose more than 10%. The company said that Dahifei's commercialization work in China is progressing steadily","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01696":1},"content_text":"智通财经APP获悉，复锐医疗科技(01696)涨超10%，本月股价已累涨超四成。截至发稿，涨10.45%，报6.45港元，成交额1111.17万港元。消息面上，7月28日晚，复锐医疗科技公布，公司知悉市场对其再授权产品RT002(中国境内商标达希斐®，英文商标 DAXXIFY®，通用名DaxibotulinumtoxinA-lanm)于中国内地的商业化进展持续关注。公司仅此说明，于该公告日期，该产品在中国内地的商业化工作正稳步推进。监管申报、市场准入及专业团队的建设等相关业务准备工作均有序开展。公司对该产品在中国市场的应用前景充满信心，并将根据实际进展适时披露进一步信息。东北证券近期研报指出，公司能量源业务短期受到北美高利率环境和亚太等市场战略调整的影响，随外部环境改善和内部战略调整得当，主业将恢复稳健增长。此外长效肉毒达希斐有望在25-26年上市销售，显著长效优势叠加高端定位或将快速获得B端和C端市场认可。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555086457","isCrawlerRequest":true}